Our 2024 Partners

FMI_horizontal-fire-logo

Lead Partner

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.

www.foundationmedicine.com

 

Guardant Health

Expertise Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.

www.guardanthealth.com

Labcorp

Expertise Partner

Clear and confident healthcare decisions begin with questions. At Labcorp, we’re constantly pursuing answers. With unparalleled diagnostics and drug development capabilities, we accelerate innovation and provide insight to improve health and improve lives. Whether you’re a patient, provider, researcher or in the pharmaceutical industry, we’re here for you.

Learn more at www.labcorp.com or follow up on LinkedIn and Twitter @Labcorp

sysmex
gtc_logo

Expertise Partner

Sysmex Inostics Inc Collaboration with Genomic Testing Cooperative
The collaboration provides biopharma with a full suite of assay services from both companies for each phase in the clinical trial process. The companies will work jointly on improvements and new indications of the tests for use by biopharma researchers.

This partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next-generation sequencing (NGS) profiling with Sysmex Inostics's global commercial capabilities in biopharma
therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.

www.sysmex-inostics.com

genomictestingcooperative.com

GRAIL_logo

Expertise Partner

GRAIL is a healthcare company in pursuit of innovation to solve medicine’s most important challenges. Our team of leading scientists, engineers, and clinicians are on an urgent mission to detect more cancers early, when they are more treatable and potentially curable.

Our team brings together biopharma and companion diagnostics expertise with biomarker, drug-diagnostic co-development, and commercialization experience.Data from GRAIL studies have demonstrated analytically validated performance, and robust analytical sensitivity, specificity, and precision.We leverage the combination of GRAIL’s unique methylation-based liquid biopsy platform and biologically motivated machine learning capabilities. 

We aim to help our partners accelerate precision oncology across cancer indications and therapeutic modalities with research to clinical trials and, ultimately, registration and commercial launch.

www.grail.com

Natera

Expertise Partner

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA with high accuracy in identifying MRD and predicting recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types. The test is available for clinical and research use, has been designated by the FDA as a Breakthrough Device, received CE mark. Look deeper at:

www.natera.com/oncology

Tempus NEW

Expertise Partner

Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.

www.tempus.com

Oxford Biodynamics

Expertise Partner

Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring.

www.oxfordbiodynamics.com

Biotechne

Program Partner

Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.

www.bio-techne.com

angle

Program Partner

Angle Over the last six years ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. This creates new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy to assess metastatic breast cancer.

www.angleplc.com

sophia

Program Partner

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

www.sophiagenetics.com

tri star

Program Partner

TriStar is a biotechnology company specializing in the provision of quality annotated human oncology biospecimens and integrated, in-house contract research services (IHC, RNA-ISH, WES & RNAseq) for pharma, biotech, and diagnostic developers. Our ethically approved anonymized clinical samples acquired via collaborations with leading UK & European medical centers include pre/post SOC chemo & immunotherapy, and incorporate clinical follow-up, survival, response information & molecular characterization.

TriStar’s repository includes FFPE blocks with matched plasma/serum/blood, tissue microarrays (TMAs) and digital images with IHC, NGS and other molecular data.

www.tristargroup.us

Screenshot 2024-02-20 144101

Program Partner

Screenshot 2024-02-20 144306

Program Partner

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

www.personalis.com

Screenshot 2024-02-23 120806

Program Partner

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind disease at any given moment, researchers and clinicians can better target medicines to the right patients in both drug development and clinical practice. Precede seeks to improve success rates in drug development and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and therapy that is precise to the biology of their disease.

www.precede.com

Burning Rock Biotech

Exhibition Partner

Burning Rock Biotech: Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.

www.brbiotech.com

almac

Exhibition Partner

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:

  • Genomic Services (Range of Platforms & Technologies, Sample Management, Data Sciences)
  • Clinical Trial Assays (Research Use Assays, Clinical Use Assays, Global Clinical Trial Testing)
  • Companion Diagnostics (CDx Development, CDx Manufacture, CDx Commercialisation)

https://www.almacgroup.com/diagnostics/

menari

Exhibition Partner

TBC. 

Screenshot 2024-02-23 120326

Exhibition Partner

BioIVTLogo

Exhibition Partner

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

 www.bioivt.com

twin strand

Meeting Partner

TBC.

SensID

Meeting Partner

SensID GmbH is specialized in the development & manufacturing of superior reference material and quality controls for molecular diagnostics.
The company has recently introduced a novel, truly patient-like ctDNA as base reference material for liquid biopsy assays. Key features of this truly breakthrough control material include:
Superior low error rate: enables lowest LOB/LOD/LOQ – (Limit of Blank/Detection/Quantification) for NGS assays incl. MRD (Minimal Residual Disease) tests
Commutability: patient like fragmentation profile

www.sens-id.com

biodesix

Panel Partner

Biodesix, Inc. stands as a pioneering leader in the field of diagnostic solutions, employing a diverse array of technologies and a portfolio of five Medicare covered commercial tests. Utilizing a multi-omic approach that harnesses the power of genomics and proteomics, we also extend expertise in regulatory, quality systems, Market Access, and commercial requirements for diagnostic testing. As a partner to biopharma companies, we offer a comprehensive suite of services to support therapeutic development and clinical sample testing.

Biodesix enables therapeutics companies with cutting-edge technologies and guidance for biomarker discovery, assay development and validation, sample testing, and commercialization of diagnostic tests. We also provide thorough end-to-end services that cover sample management including kit manufacturing.

With a state-of-the-art facility, a track record of successful collaboration with business leaders, and unwavering commitment to diagnostic innovation, we are the ultimate choice as a diagnostic service provider.

www.biodesix.com

pillar

Panel Partner

VOLITION_PRIMARY_LOGO_POS

Spotlight Partner

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also improve their quality of life.

www.volition.com

beacon

Data Partner

We are a clinical trial and pipeline database solution designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving drug development landscape. For more information or to request a demo, visit our website:

www.beacon-intelligence.com